All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following hospital-treated infection patient populations:
Diagnosed HCAP events due to S. aureus.
Diagnosed BSI events due to CoNS.
Diagnosed BSI events due to S. aureus.
Diagnosed BSI events due to Enterococccus spp.
Diagnosed BSI events due to other gram-positive infections.
Diagnosed cIAI events due to S. aureus.
Diagnosed cIAI events due to CoNS.
… and many more (details available on request).
Note: Coverage may vary by country and region.
Source: DRG, part of Clarivate

Table of contents

  • Hospital-Treated Gram-Positive Infections - Epidemiology - Mature Markets
    • Introduction
      • Key Updates
      • Diagnosed UTI Events per 1,000 People of All Ages in 2019 and 2029
      • Relative Sizes of the Contributing Factors to the Trend in Diagnosed UTI Events in the Next Ten Years
      • Diagnosed cSSSI Events per 1,000 People of All Ages in 2019 and 2029
      • Relative Sizes of the Contributing Factors to the Trend in Diagnosed cSSSI Events in the Next Ten Years
    • Epidemiology Data
    • Methods
      • Diagnosed Urinary Tract Infection Events
      • Diagnosed Bloodstream Infection Events
      • Diagnosed Nosocomial Pneumonia Events
      • Diagnosed Complicated Intra-Abdominal Infection Events
      • Diagnosed Surgical-Site Infection Events
      • Diagnosed Complicated Skin and Skin Structure Events
      • UTI Pathogen Distribution
      • NP Pathogen Distribution
      • BSI Pathogen Distribution
      • cIAI Pathogen Distribution
      • SSI and cSSSI Pathogen Distribution
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Hospital-Treated Gram-Positive Infections
        • Studies Excluded in the Analysis of Hospital-Treated Gram-Positive Infections
      • Risk/Protective Factors
        • Risk/Protective Factors for Hospital-Treated Gram-Positive Infections
      • Bibliography
      • Glossary

Author(s): Mariah Scott; T.J. Arndt, M.P.H., C.P.H.

Mariah J. Scott, M.S., M.P.H., is an associate epidemiologist at DRG, part of Clarivate. Prior to joining DRG, Mariah investigated patient-reported outcomes on health-related quality of life during the transition from pediatric to adult care in patients with Sickle Cell Disease throughout the state of New Jersey.

Mariah received her B.S. in Molecular Biology from Montclair State University and her M.S. from Seton Hall University where she studied Microbiology and Immunology. Ms. Scott also holds a M.P.H. in Epidemiology from Rutgers University.

Thomas J. Arndt, M.P.H., C.P.H., is an epidemiologist at DRG, part of Clarivate. He earned his master's degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.